P/E ratio for Sumitomo Pharma (4506.T)
P/E ratio as of April 2024 (TTM): -1.07
According to Sumitomo Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.07147. At the end of 2022 the company had a P/E ratio of -47.0.
P/E ratio history for Sumitomo Pharma from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -47.0 | -388.36% |
| 2021 | 16.3 | 80.44% |
| 2020 | 9.03 | -43.86% |
| 2019 | 16.1 | -42.65% |
| 2018 | 28.0 | 92.37% |
| 2017 | 14.6 | -43.57% |
| 2016 | 25.8 | -10.07% |
| 2015 | 28.7 | 22.82% |
| 2014 | 23.4 | -55.86% |
| 2013 | 53.0 | 96.1% |
| 2012 | 27.0 | -4.81% |
| 2011 | 28.4 | 29.74% |
| 2010 | 21.9 | 35.67% |
| 2009 | 16.1 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.